NEW YORK, Jun 05 (Reuters) - Drug maker Teva Pharmaceutical Industries Ltd. said on Friday that its multiple sclerosis treatment has been recommended for approval by the UK Licensing Authority and that marketing authorization for the drug is expected to follow shortly.
Copaxone (glatiramer) is used to treat relapsing-remitting multiple sclerosis. Following the approval in the United Kingdom, Teva will initiate the mutual recognition procedure to make the drug available in the remainder of the European Union (EU) and will ask the United Kingdom to act as the reference member state.
The successful completion of this procedure would enable the launch of Copaxone in the EU during the first half of 2001, the company said.
Shares of Teva on Friday were down 1-7/16 at 51-5/8 on the NASDAQ exchange.